New combo therapy aims to reverse liver damage in hepatitis b patients
Disease control
Not yet recruiting
This study tests whether adding peginterferon alfa-2b to standard antiviral drugs can improve liver health in people with compensated cirrhosis caused by hepatitis B. Thirty adults will be randomly assigned to receive either the combination or antivirals alone for 48 weeks. Resea…
Phase: NA • Sponsor: Xiamen Humanity Hospital • Aim: Disease control
Last updated Jun 26, 2026 18:55 UTC